Cognetivity Neurosciences to Attend HLTH 2022 in Las Vegas and Appoints New Advisory Board Member
Cognetivity Neurosciences to Attend HLTH 2022 in Las Vegas and Appoints New Advisory Board Member
Both announcements signal company's intentions for US commercial expansion with FDA-registered, market-ready brain health screening platform
這兩項聲明都標誌着該公司有意通過FDA註冊的、市場就緒的腦健康篩查平臺在美國進行商業擴張
Vancouver, British Columbia--(Newsfile Corp. - November 10, 2022) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) (the "Company" or "Cognetivity"), a technology company that has created a unique brain health screening platform for use in medical, commercial and consumer environments, today announces that it will be attending the HLTH 2022 conference next week. It also announces that it has appointed Dr. Lance Black, MD, MBID, to its advisory board with immediate effect.
温哥華，不列顛哥倫比亞省-(Newsfile Corp.-2022年11月10日)-認知神經科學有限公司。(CSE：CGN)(OTCQB：CGNSF)(FSE：1UB)(“公司”或“認知力”)，一家創造了用於醫療、商業和消費環境的獨特腦健康篩查平臺的科技公司今天宣佈，它將參加下週舉行的HLTH 2022大會。該公司還宣佈，它已任命醫學博士蘭斯·布萊克博士為其顧問委員會成員，立即生效。
Taking place this year at The Venetian Expo in Las Vegas, NV, from 13 to 16 November, HLTH is one of the world's leading events in healthcare innovation and transformation. It aims to gather senior leaders across the health ecosystem to solve healthcare's most pressing problems and realize the most promising opportunities to create health's future. Among the thousands of attendees at this year's conference, there will be healthcare payers and providers, government entities, pharmaceutical and life sciences companies, startups and investors, and broader tech companies and solution providers. These include Kaiser Permanente, Biogen, HCA Healthcare, the US Department of Health and Human Services (HHS), the Center for Medicare and Medicaid Innovation, Amazon and Google.
HLTH於今年11月13日至16日在內華達州拉斯維加斯舉行的威尼斯人博覽會上舉行，是世界領先的醫療創新和轉型活動之一。它的目的是聚集整個衞生生態系統的高級領導人，以解決醫療保健最緊迫的問題，並實現創造衞生未來的最有希望的機會。在今年會議的數千名與會者中，將有醫療保健支付者和提供者、政府實體、製藥和生命科學公司、初創企業和投資者，以及更廣泛的科技公司和解決方案提供商。這些公司包括Kaiser Permanente、Biogen、HCA Healthcare、美國衞生與公眾服務部(HHS)、醫療保險和醫療補助創新中心、亞馬遜和谷歌。
Cognetivity will have booth 3229 at HLTH 2022, shared with its partner, the world-leading data and interoperability platform provider InterSystems. Headquartered in Cambridge, Massachusetts, InterSystems counts Mass General Brigham, Roche Diagnostics, the US Veterans Association and the UK National Health Service (NHS) among its customers. Over one billion health records worldwide are managed using InterSystems technology, and the 20 best hospitals in the US, according to the latest US News & World Report rankings, all use InterSystems products. These include Mayo Clinic, Cleveland Clinic and The Johns Hopkins Hospital.
Cognetivity將在2022年HLTH上擁有3229號展位，與其合作伙伴--世界領先的數據和互操作平臺提供商InterSystems共享。InterSystems總部設在馬薩諸塞州劍橋市，其客户包括麻省總醫院Brigham、羅氏診斷公司、美國退伍軍人協會和英國國家醫療服務體系(NHS)。全球超過10億份健康記錄是使用InterSystems技術管理的，根據最新的《美國新聞與世界報道》排名，美國最好的20家醫院都使用InterSystems產品。這些醫院包括梅奧診所、克利夫蘭診所和約翰霍普金斯醫院。
In all, Cognetivity's attendance at HLTH represents an excellent opportunity for the company to expand its commercial network and presence in the US market.
總而言之，Cognetivity參加HLTH是該公司擴大其在美國市場的商業網絡和存在的絕佳機會。
The news comes at the same time as the company's announcement that Dr. Lance Black has joined the company's advisory board. Lance currently serves as Senior Medical Director of 3ive Labs and Chief Medical Officer to XN Health. As an engineer, physician, and innovator, he speaks a multitude of technical languages and serves as an intermediary and catalyst in the ever-demanding path of medical device and digital health development.
與此同時，該公司宣佈蘭斯·布萊克博士加入了該公司的顧問委員會。蘭斯目前擔任3ve實驗室的高級醫療董事和XN Health的首席醫療官。作為一名工程師、醫生和創新者，他會説多種技術語言，並在醫療器械和數字健康發展日益苛刻的道路上充當中間人和催化劑。
His prior experience also includes serving as a Family and Flight Medicine physician in the USAir Force; Medical Affairs Manager for a MedTech development firm where he participated in the build-out and testing of over 25 medical devices with contribution on more than 30 patents; and, most recently, Associate Director of Texas Medical Center's TMC Innovation, focused on building and launching novel medical device and digital health companies.
他之前的經歷還包括在美國空軍擔任家庭和飛行醫學醫生；在一家MedTech開發公司擔任醫療事務經理，參與了超過25台醫療設備的建設和測試，獲得了30多項專利；最近，他在德克薩斯州醫療中心的TMC Innovation擔任董事助理，專注於建立和推出新型醫療設備和數字健康公司。
During his tenure at TMC Innovation, Lance had the opportunity to review and screen over 2000 healthcare startups for entry into the well-known accelerator, TMCx. He advised over 100 medical device and digital health companies who have collectively raised more than USD 2.5 billion, and aided in the launch of 10 healthcare startups as advisor to TMC Biodesign, who have now raised over USD 30 million.
在TMC Innovation任職期間，蘭斯有機會審查和篩選了2000多家醫療保健初創公司，以加入著名的加速器TMCx。他為100多家醫療設備和數字健康公司提供諮詢服務，這些公司總共籌集了超過25億美元的資金，並作為TMC BioDesign的顧問幫助啟動了10家醫療初創公司，這些公司現在已經籌集了超過3000萬美元的資金。
Lance's education includes a BS in Biological Engineering from Louisiana State University, an MD from LSU Health Sciences Center in New Orleans, and a Masters of Biomedical Innovation & Development (MBID) from Georgia Tech.
蘭斯的教育包括路易斯安那州立大學生物工程學士學位、新奧爾良路易斯安那州立大學健康科學中心醫學博士學位和佐治亞理工學院生物醫學創新與開發碩士學位。
"I'm thrilled to be joining the Cognetivity board," Lance confirmed. "I have got to know the team very well in recent years as part of their selection for and participation in the TMCx accelerator program. I'm very excited about their technology and its capabilities in the brain health space, where innovative approaches are needed more than ever, and I can't wait to use my experience and network to help accelerate their US commercial expansion."
蘭斯證實説：“我很高興能加入認知能力委員會。”近年來，作為他們選擇和參與TMCx加速器計劃的一部分，我對這個團隊非常瞭解。我對他們在大腦健康領域的技術及其能力感到非常興奮，這一領域比以往任何時候都更需要創新方法，我迫不及待地想利用我的經驗和網絡幫助他們加快在美國的商業擴張。
Also commenting on the announcement, Cognetivity's CEO, Dr. Sina Habibi, said: "We're very happy to welcome Lance to our advisory board. His experience with innovative digital health companies in the US market is immense. It's a fantastic validation of our technology and commercial approach that he has seen our work up close and is keen to further his involvement - we can't wait to begin working with him in this new role."
Cognetivity的首席執行官Sina Habibi博士也對這一聲明發表了評論，他説：“我們非常高興歡迎蘭斯加入我們的顧問委員會。他在美國市場上與創新的數字健康公司合作的經驗非常豐富。他近距離觀察了我們的工作，並熱衷於進一步參與-我們迫不及待地想開始與他在這個新角色上合作，這是對我們技術和商業方式的極好證明。”
About Cognetivity Neurosciences Ltd.
關於認知性神經科學有限公司
Cognetivity is a technology company that has created a cognitive testing platform for use in medical, commercial and consumer environments. Cognetivity's ICA uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of cognitive impairment by testing the performance of large areas of the brain. The ICA is currently available for clinical use in the USA, UK and Europe, with regulatory approval for other regions planned for 2022.
Cognetivity是一家技術公司，它創建了一個認知測試平臺，用於醫療、商業和消費環境。Cognetivity的ICA使用人工智能和機器學習技術，通過測試大腦大片區域的表現來幫助檢測認知障礙的最早跡象。ICA目前可在美國、英國和歐洲用於臨牀，其他地區的監管批准計劃於2022年進行。
ON BEHALF OF THE BOARD
我代表董事會
"Sina Habibi"
Sina Habibi
Chief Executive Officer and Director
《新浪哈比比》
新浪哈比比
董事首席執行官兼首席執行官
FORWARD-LOOKING STATEMENTS:
前瞻性陳述：
Certain statements included in this news release constitute forward-looking information or statements (collectively, "forward-looking statements"), including those identified by the expressions "anticipate", "assume" "believe", "plan", "estimate", "expect", "intend", "may", "should" and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This news release contains forward looking statements. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Such statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Readers should not place undue reliance on the Company's forward-looking statements.
本新聞稿中包含的某些陳述構成前瞻性信息或陳述(統稱為“前瞻性陳述”)，包括“預期”、“假設”、“相信”、“計劃”、“估計”、“預期”、“打算”、“可能”、“應該”以及與公司或其管理層有關的類似表述。前瞻性陳述不是歷史事實，但反映了對未來結果或事件的當前預期。本新聞稿包含前瞻性陳述。這些前瞻性陳述不是對未來業績的保證，涉及難以預測的風險、不確定因素和假設。此類陳述基於當前預期和各種估計、因素和假設，涉及已知和未知的風險、不確定性和其他因素。這些陳述和信息是基於對目前和未來的業務戰略以及公司未來運營環境的許多假設。除非法律要求，否則公司不承擔更新或修改前瞻性信息以反映新事件或新情況的責任。讀者不應過分依賴該公司的前瞻性陳述。
The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
加拿大證券交易所不對本新聞稿的充分性或準確性承擔責任。
For further information: Please visit: or contact: info@cognetivity.com; For media enquiries, please contact: Josh Stanbury, josh@sjspr.co, 416-628-7441
有關更多信息，請訪問：請訪問：或聯繫：info@cognetivity.com；如有媒體查詢，請聯繫：Josh Stanbury，Josh@sjSpr.co，416-628-7441
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。